Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom announced CE Mark approval for its G7 Continuous Glucose Monitoring (CGM) System, enhancing diabetes management for users in Europe aged two years and older, including pregnant women. The G7 is designed to be more powerful and user-friendly, with a 30-minute sensor warmup time, no fingersticks required, and real-time glucose readings sent to compatible devices. The system reduces blood sugar fluctuations and increases time in range, supporting better health outcomes.
Dexcom, Inc. (NASDAQ: DXCM) received approval from the Ontario government for coverage of its Dexcom G6 CGM System through the Assistive Devices Program, effective March 14, 2022. This initiative benefits individuals with type 1 diabetes over the age of 2 who meet specific criteria, expanding access to this innovative glucose monitoring technology. Ontario joins six other provinces in offering public coverage for continuous glucose monitoring, enhancing diabetes management and potentially reducing long-term health complications.
Dexcom (NASDAQ:DXCM) has received Breakthrough Device Designation from the FDA for its continuous glucose monitoring (CGM) system, aimed at improving glycemic management in hospital settings. This designation accelerates the regulatory review process, enabling faster market access for the technology. In prior studies involving over 800 patients during the pandemic, Dexcom CGM demonstrated enhanced glucose control without increased hypoglycemia risk. Experts anticipate that this designation will significantly advance in-patient care capabilities.
DexCom, Inc. (NASDAQ:DXCM) announced upcoming presentations at virtual investor conferences. Brice Bobzien, Vice President of Finance, will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 5:00 PM (EST). Jereme Sylvain, Executive Vice President and CFO, will present at the Citi 2022 Healthcare Services Conference on February 23, 2022, at 10:15 AM (EST). Webcast links will be available on the Dexcom Investor Relations website, where they will also be archived for future access.
DexCom, Inc. (Nasdaq: DXCM) reported Q4 2021 revenue of $698.2 million, a 23% increase year-over-year, with U.S. growth at 15% and international at 54%. Full year revenue rose 27% to $2.45 billion. However, GAAP operating income fell sharply to $0.6 million, a decline of 1,820 basis points compared to Q4 2020. The company reiterated its 2022 revenue guidance of $2.82 - 2.94 billion. DexCom aims for a strong market position with the upcoming G7 CGM System and emphasized improved access to diabetes technology.
Dexcom, a leader in continuous glucose monitoring (CGM), announced that the Dexcom G6 CGM System is now publicly covered by Alberta Health for children under 18 requiring insulin therapy. This initiative aims to enhance diabetes management for young patients, reducing A1C levels and the likelihood of hypoglycemic incidents. With this expansion, Alberta joins other jurisdictions providing CGM coverage, facilitating access to crucial diabetes technology. The system offers real-time glucose monitoring, alerts, and support for families managing their child's diabetes effectively.
DexCom, Inc. (NASDAQ:DXCM) will release its fourth quarter and full year 2021 financial results after market close on February 10, 2022. A conference call to discuss the results will follow at 4:30 p.m. ET. Investors can access the call via phone or through a webcast on the investor relations website.
Headquartered in location value="LU/us.ca.sandgo"San Diego, California, DexCom focuses on innovative continuous glucose monitoring systems to improve diabetes management.
DexCom, Inc. (Nasdaq: DXCM) anticipates fourth quarter 2021 preliminary revenue of approximately $698 million, a 23% increase year-over-year. U.S. revenue is expected to reach $517 million (up 15%), while international revenue is estimated at $181 million, marking a growth of 54%. Full fiscal 2021 revenue is projected at $2.448 billion, a 27% increase. For 2022, guidance indicates a revenue range of $2.82 billion to $2.94 billion, representing 15-20% growth, driven by increasing CGM adoption.
DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, starting at approximately 10:30 AM EST. The virtual presentation will be webcasted, and interested parties can access it through the DexCom Investor Relations website. DexCom is a leader in diabetes care technology, focusing on innovative continuous glucose monitoring (CGM) systems to improve diabetes management worldwide.
DexCom, Inc. (NASDAQ:DXCM) announced that Jereme Sylvain, CFO, will present an update at the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021, at 2:30 PM (ET). The presentation will be webcasted, and details can be found on the company's investor relations website.
Headquartered in San Diego, California, DexCom specializes in innovative continuous glucose monitoring (CGM) technologies, aiding diabetes management.